HDP-101, an ADC, received FDA fast track designation for multiple myeloma, highlighting its potential in addressing unmet medical needs. Phase 1/2a trials show HDP-101's promising efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results